Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Sold by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC decreased its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 40.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 10,467 shares of the company’s stock after selling 6,982 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Intellia Therapeutics were worth $234,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. International Assets Investment Management LLC purchased a new position in shares of Intellia Therapeutics during the fourth quarter worth $715,000. Charles Schwab Investment Management Inc. boosted its holdings in Intellia Therapeutics by 2.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 700,228 shares of the company’s stock valued at $21,350,000 after purchasing an additional 18,987 shares during the period. BNP Paribas Financial Markets boosted its holdings in Intellia Therapeutics by 0.9% in the fourth quarter. BNP Paribas Financial Markets now owns 210,161 shares of the company’s stock valued at $6,408,000 after purchasing an additional 1,930 shares during the period. Dimensional Fund Advisors LP boosted its holdings in Intellia Therapeutics by 5.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,170,829 shares of the company’s stock valued at $35,704,000 after purchasing an additional 60,748 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in Intellia Therapeutics by 23.3% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 8,204 shares of the company’s stock valued at $242,000 after purchasing an additional 1,553 shares during the period. Institutional investors and hedge funds own 88.77% of the company’s stock.

Analyst Upgrades and Downgrades

NTLA has been the subject of a number of recent research reports. StockNews.com upgraded Intellia Therapeutics to a “sell” rating in a report on Thursday, June 27th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $65.00 target price on shares of Intellia Therapeutics in a report on Monday, June 24th. JPMorgan Chase & Co. decreased their target price on Intellia Therapeutics from $61.00 to $55.00 and set an “overweight” rating for the company in a report on Monday, August 12th. Stifel Nicolaus decreased their price target on Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating for the company in a report on Wednesday, September 11th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $73.00 price target on shares of Intellia Therapeutics in a report on Thursday, June 27th. One research analyst has rated the stock with a sell rating, four have given a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Intellia Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $61.77.

Intellia Therapeutics Stock Up 6.8 %

Shares of NTLA stock opened at $22.07 on Monday. The stock has a market capitalization of $2.24 billion, a PE ratio of -4.12 and a beta of 1.77. Intellia Therapeutics, Inc. has a 52-week low of $19.21 and a 52-week high of $36.25. The stock’s 50-day moving average price is $23.41 and its 200 day moving average price is $24.40.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.29). The company had revenue of $7.00 million during the quarter, compared to analysts’ expectations of $19.68 million. The firm’s revenue for the quarter was down 48.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.40) EPS. Analysts expect that Intellia Therapeutics, Inc. will post -5.19 earnings per share for the current fiscal year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.